MAHWAH, N.J., May 21, 2018 /PRNewswire/ — Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its leading…Original Article
Glenmark Pharmaceuticals Announces the Company’s First NDA for Ryaltris for Patients with Seasonal Allergic Rhinitis
